VTGN News and Press, VistaGen Therapeutics Inc. From 02/06/24

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, February 13, 2024, at 2:00 p.m. Pacific Time (5...

Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...

2024-01-26 09:04:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and lo...

Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received a notice of intention to grant a patent...

Preclinical data in four well-established preclinical models of pain associated with tissue inflammation and nerve injury demonstrate AV-101’s robust effects similar to gabapentin but with a better side effect profile Phase 1 data demonstrate AV-101 is well-tolerated, with no m...

2023-12-22 18:24:37 ET Summary Positive results achieved in phase 3 PALISADE-2 study for Fasedienol, a potential new treatment for social anxiety disorder. It is estimated that there are roughly 25 million people in the United States with this disorder. Itruvone is being advan...

2023-12-07 08:27:08 ET MicroAlgo  ( MLGO ) +74% plans to establish a practice base to train graduate students for the university. Altisource Asset Management  ( AAMC ) +23% Asset case against six defendants in suit v. BlackRock, Pimco can proceed. ...

2023-11-14 15:18:06 ET More on VistaGen Therapeutics Vistagen Therapeutics, Inc. (VTGN) Q2 2024 Earnings Call Transcript VistaGen Therapeutics GAAP EPS of -$0.66 beats by $0.02, revenue of $0.28M Vistagen prices $100M underwritten offering Seeking Alphaȁ...

2023-11-10 10:12:02 ET Vistagen Therapeutics, Inc. (VTGN) Q2 2024 Earnings Conference Call November 09, 2023 05:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chief Executive Officer Cindy Anderson - Chief ...

2023-11-09 17:07:10 ET More on VistaGen Therapeutics Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Call Transcript Vistagen prices $100M underwritten offering Vistagen in pact to issue a potential license for hot flashes therapy in Japan Seeking Alpha&#...